These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16516553)

  • 1. What's happening: Scotblood 2005. The donor, the product, the patient: how are we shaping up for the 21st century?
    Bessos H; Seghatchian J
    Transfus Apher Sci; 2006 Apr; 34(2):227-32. PubMed ID: 16516553
    [No Abstract]   [Full Text] [Related]  

  • 2. The future of automated red blood cell collection.
    Smith JW; Gilcher RO
    Transfus Apher Sci; 2006 Apr; 34(2):219-26. PubMed ID: 16513424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of 2-RBC donation: donor and recipient considerations.
    Popovsky MA
    Transfus Apher Sci; 2006 Aug; 35(1):3-4. PubMed ID: 16942916
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of the leuko-reductive efficacy of single-donor erythropheresis procedures].
    Domingo JM; Rabasa P; Chueca P; Medarde A
    Sangre (Barc); 1999 Jun; 44(3):238-40. PubMed ID: 10481589
    [No Abstract]   [Full Text] [Related]  

  • 5. [The status of blood component therapy in East Germany].
    Fünfhausen G
    Beitr Infusionsther; 1988; 21():354-6. PubMed ID: 2463009
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of RBC apheresis and whole blood donation in allogeneic and autologous blood donors.
    Popovsky MA
    Transfus Apher Sci; 2006 Apr; 34(2):205-11. PubMed ID: 16513425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The donor of blood and its components.
    Högman CF
    Schweiz Med Wochenschr Suppl; 1991; 43():111-4. PubMed ID: 1843033
    [No Abstract]   [Full Text] [Related]  

  • 8. What's happening - Scotblood 2006 advances in immunetolerance, information technology, microarrays and pathogen inactivation in transfusion medicine.
    Bessos H; Fraser R; Seghatchian J
    Transfus Apher Sci; 2006 Oct; 35(2):173-7. PubMed ID: 17107823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood component therapy today].
    Rebulla P; Bertolini F; Porretti L; Marangoni F; Smacchia C; Sirchia G
    Haematologica; 1991 Jun; 76 Suppl 3():405-10. PubMed ID: 1752540
    [No Abstract]   [Full Text] [Related]  

  • 10. Scotblood 2015: Improving and delivering blood products, novel cellular therapies, and celebrating patients and donor engagement within transfusion services.
    Colligan D; McGowan N; Seghatchian J
    Transfus Apher Sci; 2016 Aug; 55(1):164-8. PubMed ID: 27524267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care.
    Newman B
    Transfusion; 2004 Oct; 44(10):1535-7; author reply 1537-8. PubMed ID: 15383032
    [No Abstract]   [Full Text] [Related]  

  • 12. What do we know?
    Muylle L
    Acta Anaesthesiol Belg; 2002; 53(2):105-10. PubMed ID: 12146097
    [No Abstract]   [Full Text] [Related]  

  • 13. What's going on in LDL apheresis.
    Onofrillo D; Accorsi P
    Transfus Apher Sci; 2007 Dec; 37(3):213-21. PubMed ID: 18054286
    [No Abstract]   [Full Text] [Related]  

  • 14. [Apheresis donation. Current views and perspectives].
    Schooneman F
    Transfus Clin Biol; 2005 Jun; 12(2):208-11. PubMed ID: 15925528
    [No Abstract]   [Full Text] [Related]  

  • 15. In this substantial issue we have an important International Forum from Turkey, a very interesting What's Happening section, and an excellent Theme section.
    Rock G
    Transfus Apher Sci; 2012 Jun; 46(3):233. PubMed ID: 22503404
    [No Abstract]   [Full Text] [Related]  

  • 16. Why do we believe in red cell transfusion?
    McClelland B
    Dev Biol (Basel); 2007; 127():3-8. PubMed ID: 17486877
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing indications for red cell transfusion.
    Ballard S; Staves J; Murphy MF
    Transfus Med; 2007 Aug; 17(4):315-6; author reply 317. PubMed ID: 17680959
    [No Abstract]   [Full Text] [Related]  

  • 18. The six questions of pathogen reduction technology: an overview of current opinions.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current (safety) issues in the screening of donor blood and the preparation of pure blood components. November 7-8, 1985. Oss, The Netherlands.
    Vox Sang; 1986; 51 Suppl 1():1-72. PubMed ID: 3739328
    [No Abstract]   [Full Text] [Related]  

  • 20. Scotblood 2010: key presentations of the past, present, and future of transfusion medicine to mark Scottish national blood transfusion service (SNBTS) anniversaries.
    Bessos H; Fraser R; Seghatchian J
    Transfus Apher Sci; 2011 Oct; 45(2):213-21. PubMed ID: 21840760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.